Tenilsetam prevents early diabetic retinopathy without correcting pericyte loss

Thrombosis and Haemostasis

Volumn 95, Issue 4, 2006, Pages 689-695

  Hoffmann, Jennifer ^a   Alt, Alex ^a   Lin, Jihong ^b   Lochnit, Günther ^a   Schubert, Uwe ^a   Schleicher, Erwin ^c   Chavakis, Triantaphyllos ^d   Brownlee, Michael ^e   Van der Woude, Fokko J ^b   Preissner, Klaus T ^a   Hammes, Hans Peter ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d NATIONAL CANCER INSTITUTE   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Endothelial survival; Experimental diabetic retinopathy; Pericytes; Tenilsetam; VEGF

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CYTOKINE; GLUCOSE; IRON CHELATING AGENT; STREPTOZOCIN; TENILSETAM; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; BOVIDS; CAPILLARY; CELL FUNCTION; CELL INTERACTION; CELL LOSS; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE; LONG TERM CARE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; UPREGULATION;

ANIMALS; CELL PROLIFERATION; CHELATING AGENTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ENDOTHELIUM, VASCULAR; HUMANS; LEUKOCYTES; MALE; PERICYTES; PIPERAZINES; RATS; RATS, WISTAR; THIOPHENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33645733382     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-11-0725     Document Type: Article

References (45)

1. Cogan DG, et al. Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol 1961; 66: 366-78.
2. Kuwabara T, Cogan DG. Retinal vascular patterns. VII. Acellular change. Invest Ophthalmol 1965; 4: 1049-64.
3. Bresnick GH, et al. Clinicopathologic correlations in diabetic retinopathy. II. Clinical and histologic appearances of retinal capillary microaneurysms. Arch Ophthalmol 1977; 95: 1215-20.
4. Orlidge A, D'Amore P. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J Cell Biol 1987; 105: 1455-62.
5. Hammes H-P, et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 2004; 53: 1104-10.
6. Engerman R, et al. Relationship of microvascular disease in diabetes to metabolic control. Diabetes 1977; 26: 760-9.
7. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
8. Lee AYW, Chung SSM. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 1999; 13: 23-30.
9. Koya D, King G. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-66.
10. Kolm-Litty V, et al. Glucosamine induces translocation of protein kinase C isoenzymes in mesangial cells. Exp Clin Endocrinol Diabetes 1998; 106: 377-83.
11. Brownlee M, et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-32.
12. Hammes H, et al. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. PNAS 1991; 88: 11555-8.
13. Stitt A, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002; 51: 2826-32.
14. Kowluru RA, et al. Abnormalities of retinal metabolism in diabetes or experimental galactosemia VIII. Prevention by aminoguanidine. Curr Eye Res 2000; 21: 814-9.
15. Corbett JA, et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992; 41: 552-6.
16. Du Y, et al. Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem 2002; 80: 771-9.
17. Kumari K, et al. Inhibition of diabetes-associated complications by nucleophilic compounds. Diabetes 1991; 40: 1079-84.
18. Giardino I, et al. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 1998; 47: 1114-20.
19. Hammes HP, Bartmann A, Engel L, et al. Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartine. Diabetologia 1997; 40: 629-34.
20. Millen AE, et al. Relation between intake of vitamins C and E and risk of diabetic retinopathy in the Atherosclerosis Risk in Communities Study. Am J Clin Nutr 2004; 79: 865-73.
21. Kowluru RA, et al. Abnormalities of retinal metabolism in diabetes and experimental galactosemia: VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 2001; 50: 1938-42.
22. Price DL, et al. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 2001; 276: 48967-72.
23. Shoda H, et al. Inhibitory effects of tenilsetam on the Maillard reaction. Endocrinology 1997; 138: 1886-92.
24. Münch G, et al. The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. J Neural Transm Park Dis Dement Sect 1994; 8: 193-208.
25. Hammes HP, et al. Acceleration of experimental diabetic retinopathy in the rat by omega-3 fatty acids. Diabetologia 1996; 39: 251-5.
26. Burrows JL, Coppin FG. Determination of tenilsetam in human plasma and urine by high-performance liquid chromatography. J Chromatogr 1990; 529: 486-93.
27. Jaffe EA, et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-56.
28. Schor AM, Schor SL. The isolation and culture of endothelial cells and pericytes from the bovine retinal microvasculature: a comparative study with large vessel vascular cells. Microvasc Res 1986; 32: 21-38.
29. Nishikawa T, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90.
30. Nehls V, Drenckhahn D. A microcarrier-based co-cultivation system for the investigation of factors and cells involved in angiogenesis in three-dimensional fibrin matrices in vitro. Histochem Cell Biol 1995; 104: 459-66.
31. Chavakis T, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003; 198: 1507-15.
32. Chavakis T, et al. The junctional adhesion molecule-C promotes neutrophil transendothelial migration in vitro and in vivo. J Biol Chem 2004; 279: 55602-8.
33. Stuchbury G, Munch G. Alzheimer's associated inflammation, potential drug targets and future therapies. J Neural Transm 2005; 112: 429-53.
34. Lindahl P, et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277: 242-5.
35. Hammes H-P, et al. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 2002; 51: 3107-12.
36. Enge M, et al. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic reti-opathy. EMBO J 2002; 21: 4307-16.
37. Webster J, et al. The carbonyl scavengers aminoguanidine and tenilsetam protect against the neurotoxic effects of methylglyoxal. Neurotox Res 2005; 7: 95-101.
38. Thornalley PJ. Glyoxalase 1-structure, function and a critical role in the enzymatic defence against glycation. Biochem See Trans 2003; 31: 1343-8.
39. Kowluru RA, Odenbach S. Effect of long-term administration of α-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 2004; 53: 3233-8.
40. Metzen E, Ratcliffe PJ. HIF hydroxylation and cellular oxygen sensing. Biol Chem 2004; 385: 223-30.
41. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9: 677-84.
42. Hammes H, et al. Upregulation of the vascular endothelial growth factor/ vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998; 47: 401-6.
43. Raab S, et al. Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thromb Haemost 2004; 91: 595-605.
44. Miyamoto K, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. PNAS 1999; 96: 10836-41.
45. Ben-Mahmud BM, et al. Tumor necrosis factor-α in diabetic plasma increases the activity of core 2 GlcNAc-T and adherence of human leukocytes to retinal endothelial cells: significance of core 2 GlcNAc-T in diabetic retinopathy. Diabetes 2004; 53: 2968-76.